Brief: Eledon Pharmaceuticals Reports Fourth Quarter And Full-Year 2020 Operating And Financial Results
30/03/2021 21:28
March 30 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PHARMACEUTICALS REPORTS FOURTH QUARTER AND
FULL-YEAR 2020
OPERATING AND FINANCIAL RESULTS
* Q4 LOSS PER SHARE $2.13
* Q4 EARNINGS PER SHARE ESTIMATE $-1.54 -- REFINITIV IBES
DATA
* HAD APPROXIMATELY $114.2 MILLION IN CASH AND CASH
EQUIVALENTS AS
OF DECEMBER 31, 2020
* ELEDON PHARMACEUTICALS - BELIEVES IT HAS SUFFICIENT
FINANCIAL
RESOURCES TO FUND UP TO FOUR PHASE 2 CLINICAL TRIALS WITH
AT-1501
* BELIEVES IT HAS SUFFICIENT FINANCIAL RESOURCES TO FUND
OPERATING
ACTIVITIES WELL INTO 2023
Source text for Eikon: ID:nGNX2RcBnw
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial